Email: [email protected] EDIToR ... receive IPNA news, reminders & useful information from other groups ... Lisa Nolan Tel: 042-9692403 e-mail: [email protected] ...... against self-antigens (auto-antigens).9,10 It is recognised that the.
9MB Sizes 4 Downloads 116 Views
The Journal of the Irish Practice Nurses Association Issue 6 Volume 5 November / December 2012

Malnutrition in the elderly


Catherine Kirrane – PN of the Year

Deirdre Mulry

Rheumatoid arthritis and psoriatic arthritis Part 1

Type 2 diabetes: research into PN attitudes Mairead Mannion Paul Marsden

Patricia Minnock

Post natal depression

Data protection: tips for branch committee members

Dr Patricia Leahy-Warren

Lisa Nolan

Are your patients at risk? age 65+

chronic lung, heart or renal disease


weakened immune system


other at-risk groups*

Pneumococcal Disease Vaccinate your at-risk patients and those 65 years and over against serious pneumococcal disease.

Information about adverse event reporting can be found at www.imb.ie. Adverse events and inadvertent vaccination during pregnancy should also be reported to Sanofi Pasteur MSD by calling 00 44 1628 785291. Further information is available on request or in the SPC. * See Immunisation Guidelines for Ireland www.immunisation.ie



Marketing authorisation holder: Sanofi Pasteur MSD Limited, Block A, Second Floor, Cookstown Court, Old Belgard Road, Tallaght, Dublin 24. Marketing authorisation number: PA 544/21/3 Legal category: POM




08/12 IR00150b

s r e n n i w g n Produci

since 2002

With a long-term record of success in reducing symptoms, exacerbations and hospitalisations vs placebo, SPIRIVA® is a LAMA you can count on to help lead your COPD patients to everyday victories.1,2

Founded on a decade of proven success LAMA = long-acting muscarinic antagonist. References: 1. SPIRIVA® 18 μg Inhalation powder, hard capsule - Summary of Product Characteristics. http://www.medicines.ie. Accessed August 2012. 2. Tashkin DP et al. for the UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543–1554. Prescribing Information (Ireland) SPIRIVA® (tiotropium) Inhalation powder, hard capsules containing 18 microgram tiotropium (as bromide monohydrate). Indication: Tiotropium is indicated as a maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (COPD). Dose and Administration: Adults only age 18 years or over: Inhalation of the contents of one capsule once daily from the HandiHaler® device. Contraindications: Hypersensitivity to tiotropium bromide, atropine or its derivatives, or to the excipient lactose monohydrate which contains milk protein. Warnings and Precautions: Not for the initial treatment of acute episodes of bronchospasm, i.e. rescue therapy. Immediate hypersensitivity reactions may occur after administration of tiotropium bromide inhalation powder. Caution in patients with narrow-angle glaucoma, prostatic hyperplasia or bladder-neck obstruction. Inhaled medicines may cause inhalation-induced bronchospasm. In patients with moderate to severe renal impairment (creatinine clearance ≤ 50 ml/min) tiotropium bromide should be used only if the expected benefit outweighs the potential risk. Patients should be cautioned to avoid getting the drug powder into their eyes. They should be advised that this may result in precipitation or worsening of narrow-angle glaucoma, eye pain or discomfort, temporary blurring of vision, visual halos or coloured images

in association with red eyes from conjunctival congestion and corneal oedema. Should any combination of these eye symptoms develop, patients should stop using tiotropium bromide and consult a specialist immediately. Tiotropium bromide should not be used more frequently than once a day. Spiriva capsules contain 5.5 mg lactose monohydrate. Interactions: Although no formal drug interac